DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a French clinical-stage specialty biopharmaceutical company, closed a $281.5m public offering.
The gross proceeds included an underwritten public offering of 4,140,000 ordinary shares in the form of 8,280,000 American Depositary Shares, or ADSs, at a price to the public of $34.00 per ADS, which included an additional 1,080,000 ADSs sold pursuant to the full exercise of the underwriters’ option to purchase additional ADSs (the ADSs are listed on the Nasdaq Global Select Market under the symbol “DBVT,” and the company’s ordinary shares are listed on Euronext Paris under the symbol “DBV”).
Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Leerink Partners LLC acted as the joint book-running managers for the offering. H.C. Wainwright & Co. acted as co-manager and Bryan, Garnier & Co. acted as financial advisor in connection with the offering.
Incorporated in France in 2002, DBV Technologies has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. The company has designed two product candidates: Viaskin® Peanut and Viaskin® Milk.
Viaskin® Peanut for use in children has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.